This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Drug Therapy  • Drug Therapy, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Richard D'Aquila, MD; Bruce Walker, MD

JAMA. 1999;282:1668-1669.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Highly active antiretroviral therapy (HAART) has thus far failed to fulfill the great hope of eradicating human immunodeficiency virus 1 (HIV-1).^1-2 Not only does a reservoir of long-lived latently infected cells appear to persist for years despite apparent complete viral suppression, but as the study by Dornadula et al³ reported in this issue of THE JOURNAL shows, continuing low-level viral replication is likely to be occurring in most persons with HIV-1 apparently suppressed with HAART. However, a second article in this issue by Whitcup et al⁴ indicates that despite the apparent failure of HAART to completely control viral replication, current regimens lead to meaningful immune reconstitution and have a substantial beneficial effect on an opportunistic pathogen that only recently had been one of the most difficult to manage with chemotherapy directed against it.

Ongoing viral RNA expression and virus evolution in peripheral blood mononuclear . . . [Full Text of this Article]

Author Affiliations: Partners AIDS Research Center, Massachusetts General Hospital, Charlestown.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Residual HIV-1 RNA in Blood Plasma of Patients Taking Suppressive Highly Active Antiretroviral Therapy
Geethanjali Dornadula, Hui Zhang, Bonnie VanUitert, John Stern, Lawrence Livornese, Jr, Mark J. Ingerman, James Witek, Richard J. Kedanis, Jaan Natkin, Joseph DeSimone, and Roger J. Pomerantz
JAMA. 1999;282(17):1627-1632.
ABSTRACT | FULL TEXT  

Discontinuation of Anticytomegalovirus Therapy in Patients With HIV Infection and Cytomegalovirus Retinitis
Scott M. Whitcup, Eric Fortin, Anne S. Lindblad, Paul Griffiths, Julia A. Metcalf, Michael R. Robinson, Jody Manischewitz, Barbara Baird, Cheryl Perry, I. Michael Kidd, Tamara Vrabec, Richard T. Davey, Jr, Judith Falloon, Robert E. Walker, Joseph A. Kovacs, H. Clifford Lane, Robert B. Nussenblatt, Janine Smith, Henry Masur, and Michael A. Polis
JAMA. 1999;282(17):1633-1637.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antiretroviral Therapy: Time To Think Strategically
Cohen
ANN INTERN MED 2000;132:320-322.
FULL TEXT  

Ultra-"Ultrasensitive" Viral-Load Assays
AIDS Clin Care 2000;2000:5-5.
FULL TEXT